FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943669995> ?p ?o ?g. }

• W2943669995 endingPage "203" @default.
• W2943669995 startingPage "203" @default.
• W2943669995 abstract "Pharmacogenetic (PGx) testing is key to addressing the issue of the prevailing ‘trial-and-error’ prescribing of medications in psychiatry. Expert groups have reported high evidence levels for several gene–drug pairs related to psychotropic medications with most of the focus related to antidepressants.1 For instance, several commercially available PGx tests have been launched in psychiatric care that typically examine genetic variations of at least the CYP2C19 and CYP2D6 genes. Some companies have conducted prospective evaluation trials examining the benefits of genetic testing versus treatment as usual (TAU). The largest trial to date was recently completed and consisted of an 8-week double-blind, multicenter, randomized controlled trial (RCT) of the Genesight commercial test versus TAU in depression (N = 1167).2 While using symptom improvement as the outcome variable showed no significance (P = 0.107), patients guided by the test achieved a significant improvement in response (≥50% decrease in 17-item Hamilton Rating Scale for Depression [HAMD-17]; P = 0.013) and remission (HAMD-17 ≤ 7; P = 0.007), compared with those who received TAU. Notably, a recent meta-analysis of multigene PGx tests (incorporating the study by Greden et al.2 and four other RCTs) reported that the PGx test-guided groups (n = 887) showed significantly better remission rates (odds ratio of 1.7) compared to the non-guided (TAU) group (n = 850).3 Given that a high proportion of patients with depression is treated by primary care providers, the utility of PGx testing was evaluated in primary (N = 810) and psychiatric (N = 1061) care settings in a subset of the IMPACT project (a 7-year naturalistic study examining the effects of PGx testing).4 The response rate at follow up tended to be better in patients taking medications congruent with their combinatorial PGx test report (28.0%), in comparison with the patients taking incongruent medications (21.4%, P = 0.057). This study suggested that PGx testing appears to be at least as effective in primary care as in psychiatric care settings, though the response rate was higher in patients treated by primary care providers than in those treated by psychiatrists in this sample (response rate: 30.1% vs 22.3%, respectively, P < 0.01). In summary, PGx testing is promising for psychiatric treatment and can provide substantial benefit to patients; however, there are still several issues to be addressed. First, most studies have evaluated patients who have not responded to previous treatment, and it remains unclear whether these tests are beneficial and cost-effective enough to be applied pre-emptively for the entire patient population at the beginning of their treatment. More prospective RCTs are needed that will evaluate factors such as level of treatment resistance and cost–benefit analyses. Second, it is important to keep in mind that test panels across academic centers and industry differ substantially. For instance, the level of agreement in psychotropic medication recommendations across four PGx tests was reported to be modest as follows: antidepressants (56%), anxiolytics/hypnotics (56%), and antipsychotics (55%), with the exception of mood stabilizers (84%).5 This finding indicates that PGx tests cannot be considered as interchangeable, which highlights the need for test standardization and further prospective RCTs." @default.
• W2943669995 created "2019-05-09" @default.
• W2943669995 creator A5009531817 @default.
• W2943669995 creator A5022065571 @default.
• W2943669995 creator A5051058343 @default.
• W2943669995 date "2019-05-01" @default.
• W2943669995 modified "2023-09-27" @default.
• W2943669995 title "The coming‐of‐age of pharmacogenetic testing in clinical psychiatry" @default.
• W2943669995 cites W2804371944 @default.
• W2943669995 cites W2884150158 @default.
• W2943669995 cites W2896138992 @default.
• W2943669995 cites W2904708914 @default.
• W2943669995 cites W2908242089 @default.
• W2943669995 doi "https://doi.org/10.1111/pcn.12832" @default.
• W2943669995 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31045316" @default.
• W2943669995 hasPublicationYear "2019" @default.
• W2943669995 type Work @default.
• W2943669995 sameAs 2943669995 @default.
• W2943669995 citedByCount "0" @default.
• W2943669995 crossrefType "journal-article" @default.
• W2943669995 hasAuthorship W2943669995A5009531817 @default.
• W2943669995 hasAuthorship W2943669995A5022065571 @default.
• W2943669995 hasAuthorship W2943669995A5051058343 @default.
• W2943669995 hasBestOaLocation W29436699951 @default.
• W2943669995 hasConcept C104317684 @default.
• W2943669995 hasConcept C118552586 @default.
• W2943669995 hasConcept C126322002 @default.
• W2943669995 hasConcept C135763542 @default.
• W2943669995 hasConcept C138496976 @default.
• W2943669995 hasConcept C139719470 @default.
• W2943669995 hasConcept C156957248 @default.
• W2943669995 hasConcept C15744967 @default.
• W2943669995 hasConcept C162324750 @default.
• W2943669995 hasConcept C168563851 @default.
• W2943669995 hasConcept C2776867660 @default.
• W2943669995 hasConcept C2777198177 @default.
• W2943669995 hasConcept C2780673598 @default.
• W2943669995 hasConcept C54355233 @default.
• W2943669995 hasConcept C55775858 @default.
• W2943669995 hasConcept C558461103 @default.
• W2943669995 hasConcept C70410870 @default.
• W2943669995 hasConcept C71924100 @default.
• W2943669995 hasConcept C83849319 @default.
• W2943669995 hasConcept C86803240 @default.
• W2943669995 hasConceptScore W2943669995C104317684 @default.
• W2943669995 hasConceptScore W2943669995C118552586 @default.
• W2943669995 hasConceptScore W2943669995C126322002 @default.
• W2943669995 hasConceptScore W2943669995C135763542 @default.
• W2943669995 hasConceptScore W2943669995C138496976 @default.
• W2943669995 hasConceptScore W2943669995C139719470 @default.
• W2943669995 hasConceptScore W2943669995C156957248 @default.
• W2943669995 hasConceptScore W2943669995C15744967 @default.
• W2943669995 hasConceptScore W2943669995C162324750 @default.
• W2943669995 hasConceptScore W2943669995C168563851 @default.
• W2943669995 hasConceptScore W2943669995C2776867660 @default.
• W2943669995 hasConceptScore W2943669995C2777198177 @default.
• W2943669995 hasConceptScore W2943669995C2780673598 @default.
• W2943669995 hasConceptScore W2943669995C54355233 @default.
• W2943669995 hasConceptScore W2943669995C55775858 @default.
• W2943669995 hasConceptScore W2943669995C558461103 @default.
• W2943669995 hasConceptScore W2943669995C70410870 @default.
• W2943669995 hasConceptScore W2943669995C71924100 @default.
• W2943669995 hasConceptScore W2943669995C83849319 @default.
• W2943669995 hasConceptScore W2943669995C86803240 @default.
• W2943669995 hasIssue "5" @default.
• W2943669995 hasLocation W29436699951 @default.
• W2943669995 hasLocation W29436699952 @default.
• W2943669995 hasOpenAccess W2943669995 @default.
• W2943669995 hasPrimaryLocation W29436699951 @default.
• W2943669995 hasRelatedWork W2116228807 @default.
• W2943669995 hasRelatedWork W2350366096 @default.
• W2943669995 hasRelatedWork W2351926771 @default.
• W2943669995 hasRelatedWork W2359456137 @default.
• W2943669995 hasRelatedWork W2365700493 @default.
• W2943669995 hasRelatedWork W2376913077 @default.
• W2943669995 hasRelatedWork W2378996837 @default.
• W2943669995 hasRelatedWork W2383545306 @default.
• W2943669995 hasRelatedWork W2383855066 @default.
• W2943669995 hasRelatedWork W3030202538 @default.
• W2943669995 hasVolume "73" @default.
• W2943669995 isParatext "false" @default.
• W2943669995 isRetracted "false" @default.
• W2943669995 magId "2943669995" @default.
• W2943669995 workType "article" @default.